The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT. The main questions it aims to answer are:
* How effective is drug Sac-TMT in treating Thymic Carcinoma? * What adverse events (AEs) do participants have when taking drug Sac-TMT?
Participants will:
* Progress after at least one platinum-based chemotherapy treatment. * Take drug Sac-TMT every 2 weeks. * Take tumor response assessments every 6 weeks.
Males or females aged ≥ 18 to ≤ 75 years at the time of signing the Informed Consent Form;
Participants with histologically or cytologically confirmed thymic carcinoma, and locally advanced or metastatic thymic carcinoma who are not suitable for curative intent therapy;
Participants with advanced thymic carcinoma who have progressed after at least one prior platinum-based chemotherapy;
Able to provide a tumor tissue sample at the time of or after the diagnosis of locally advanced or metastatic tumor;
Participants with histologically or cytologically confirmed thymoma or thymic neuroendocrine tumor;
Participants with known metastases to meninges, brainstem metastases, spinal cord metastases and/or compression, active or untreated brain metastases;
Participants with other malignant tumors within 3 years prior to the first dose;
Presence of any of conditions or risk factors related to cardiovascular and cerebrovascular diseases;